 Mona Abaza
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Otolaryngology | 10 | 2021 | 72 | 3.820 |
Why?
| | Voice Disorders | 9 | 2017 | 21 | 2.110 |
Why?
| | Personnel Selection | 4 | 2019 | 66 | 1.680 |
Why?
| | Internship and Residency | 8 | 2019 | 947 | 1.680 |
Why?
| | Larynx | 4 | 2015 | 44 | 0.960 |
Why?
| | Physicians, Women | 1 | 2021 | 49 | 0.890 |
Why?
| | Leadership | 2 | 2021 | 296 | 0.740 |
Why?
| | Treatment Adherence and Compliance | 1 | 2017 | 22 | 0.690 |
Why?
| | Resilience, Psychological | 1 | 2018 | 93 | 0.650 |
Why?
| | Career Choice | 1 | 2018 | 206 | 0.620 |
Why?
| | Deglutition Disorders | 1 | 2017 | 119 | 0.610 |
Why?
| | Injections | 1 | 2015 | 164 | 0.580 |
Why?
| | Simulation Training | 1 | 2015 | 54 | 0.560 |
Why?
| | Education, Medical | 1 | 2018 | 244 | 0.560 |
Why?
| | Voice | 2 | 2017 | 13 | 0.530 |
Why?
| | Burnout, Professional | 1 | 2018 | 252 | 0.520 |
Why?
| | Education, Medical, Undergraduate | 1 | 2016 | 170 | 0.520 |
Why?
| | Patient Care Team | 1 | 2017 | 526 | 0.490 |
Why?
| | Occupational Diseases | 2 | 2006 | 145 | 0.480 |
Why?
| | Vocal Cords | 4 | 2006 | 28 | 0.480 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2020 | 182 | 0.470 |
Why?
| | Hepatitis C | 2 | 2020 | 205 | 0.440 |
Why?
| | Liver Neoplasms | 2 | 2020 | 447 | 0.400 |
Why?
| | Education, Medical, Graduate | 3 | 2019 | 379 | 0.390 |
Why?
| | Inhibin-beta Subunits | 1 | 2006 | 5 | 0.330 |
Why?
| | Activins | 1 | 2006 | 25 | 0.320 |
Why?
| | Schistosomiasis | 1 | 2006 | 34 | 0.310 |
Why?
| | Job Application | 2 | 2015 | 12 | 0.290 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2006 | 277 | 0.270 |
Why?
| | Postpoliomyelitis Syndrome | 1 | 2001 | 4 | 0.230 |
Why?
| | Glypicans | 1 | 2020 | 2 | 0.220 |
Why?
| | Dipeptidyl Peptidase 4 | 1 | 2020 | 9 | 0.220 |
Why?
| | Neurofibromatosis 2 | 2 | 1998 | 3 | 0.210 |
Why?
| | Humans | 25 | 2021 | 112255 | 0.210 |
Why?
| | Equipment Design | 2 | 2015 | 530 | 0.200 |
Why?
| | Voice Quality | 2 | 2014 | 18 | 0.200 |
Why?
| | Pilot Projects | 2 | 2019 | 1406 | 0.200 |
Why?
| | Disability Evaluation | 1 | 2000 | 305 | 0.190 |
Why?
| | United States | 4 | 2019 | 12170 | 0.180 |
Why?
| | Otolaryngologists | 1 | 2017 | 9 | 0.180 |
Why?
| | Speech-Language Pathology | 1 | 2017 | 20 | 0.170 |
Why?
| | Organizational Culture | 1 | 2018 | 128 | 0.170 |
Why?
| | Educational Status | 1 | 2019 | 406 | 0.170 |
Why?
| | Interviews as Topic | 1 | 2019 | 628 | 0.160 |
Why?
| | Clinical Clerkship | 1 | 2016 | 76 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2018 | 240 | 0.150 |
Why?
| | Psychoses, Substance-Induced | 2 | 2007 | 20 | 0.150 |
Why?
| | Competitive Behavior | 1 | 2015 | 43 | 0.150 |
Why?
| | Speech Acoustics | 1 | 2014 | 12 | 0.140 |
Why?
| | Dysphonia | 1 | 2014 | 12 | 0.140 |
Why?
| | Female | 13 | 2021 | 62627 | 0.140 |
Why?
| | Electromyography | 3 | 2007 | 328 | 0.140 |
Why?
| | Egypt | 2 | 2020 | 10 | 0.140 |
Why?
| | School Admission Criteria | 1 | 2013 | 29 | 0.130 |
Why?
| | Cell Division | 1 | 1996 | 880 | 0.130 |
Why?
| | Clinical Competence | 2 | 2019 | 904 | 0.130 |
Why?
| | Program Evaluation | 1 | 2018 | 859 | 0.130 |
Why?
| | Educational Measurement | 1 | 2016 | 300 | 0.130 |
Why?
| | Attitude | 1 | 2015 | 228 | 0.130 |
Why?
| | Correspondence as Topic | 1 | 2012 | 15 | 0.130 |
Why?
| | Surgeons | 1 | 2015 | 140 | 0.130 |
Why?
| | Students, Medical | 1 | 2016 | 272 | 0.120 |
Why?
| | Writing | 1 | 2012 | 79 | 0.120 |
Why?
| | Societies, Medical | 1 | 2016 | 764 | 0.110 |
Why?
| | Male | 13 | 2018 | 60721 | 0.110 |
Why?
| | Nasal Decongestants | 2 | 2007 | 9 | 0.100 |
Why?
| | Anti-Ulcer Agents | 2 | 2007 | 16 | 0.100 |
Why?
| | Histamine H1 Antagonists | 2 | 2007 | 36 | 0.100 |
Why?
| | Biomedical Research | 1 | 2015 | 605 | 0.090 |
Why?
| | Vocal Cord Paralysis | 2 | 2005 | 21 | 0.080 |
Why?
| | Music | 1 | 2006 | 33 | 0.080 |
Why?
| | Analgesics | 1 | 2007 | 151 | 0.080 |
Why?
| | Movement Disorders | 1 | 2005 | 55 | 0.070 |
Why?
| | Vagus Nerve Diseases | 1 | 2002 | 1 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2007 | 538 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2014 | 2817 | 0.060 |
Why?
| | Cough | 1 | 2002 | 95 | 0.060 |
Why?
| | Amyloidosis | 1 | 2001 | 41 | 0.060 |
Why?
| | Laryngeal Diseases | 1 | 2001 | 25 | 0.060 |
Why?
| | Myasthenia Gravis | 1 | 2001 | 18 | 0.060 |
Why?
| | alpha-Fetoproteins | 1 | 2020 | 39 | 0.050 |
Why?
| | Cicatrix | 1 | 2001 | 57 | 0.050 |
Why?
| | Parkinson Disease | 1 | 2005 | 402 | 0.050 |
Why?
| | Middle Aged | 7 | 2006 | 28678 | 0.050 |
Why?
| | Audiometry, Pure-Tone | 2 | 1998 | 22 | 0.050 |
Why?
| | Gastroesophageal Reflux | 1 | 2002 | 227 | 0.050 |
Why?
| | Adult | 6 | 2006 | 31793 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2001 | 211 | 0.050 |
Why?
| | Drug Prescriptions | 1 | 2001 | 260 | 0.050 |
Why?
| | Ear Neoplasms | 1 | 1998 | 5 | 0.050 |
Why?
| | Hepacivirus | 1 | 2020 | 210 | 0.050 |
Why?
| | Neurilemmoma | 1 | 1998 | 21 | 0.050 |
Why?
| | Acute Disease | 1 | 2001 | 997 | 0.050 |
Why?
| | Stroke | 1 | 2005 | 916 | 0.040 |
Why?
| | Laryngoscopy | 3 | 2002 | 69 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2001 | 664 | 0.040 |
Why?
| | Spinal Neoplasms | 1 | 1996 | 27 | 0.040 |
Why?
| | Hearing Loss | 1 | 1998 | 133 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2014 | 2878 | 0.040 |
Why?
| | Speech Production Measurement | 1 | 2014 | 14 | 0.040 |
Why?
| | Judgment | 1 | 2014 | 61 | 0.030 |
Why?
| | Follow-Up Studies | 3 | 2001 | 4888 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2014 | 138 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 328 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2020 | 1041 | 0.030 |
Why?
| | Observer Variation | 1 | 2014 | 333 | 0.030 |
Why?
| | Speech Perception | 1 | 2014 | 83 | 0.030 |
Why?
| | ROC Curve | 1 | 2014 | 486 | 0.030 |
Why?
| | Prospective Studies | 2 | 2014 | 6168 | 0.030 |
Why?
| | Aged | 4 | 2005 | 20026 | 0.030 |
Why?
| | Biomarkers | 1 | 2020 | 3465 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2021 | 0.020 |
Why?
| | Patient Selection | 1 | 2012 | 692 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 1998 | 3019 | 0.020 |
Why?
| | Age Factors | 1 | 1996 | 3330 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 1548 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 3353 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4208 | 0.020 |
Why?
| | Age Distribution | 1 | 2005 | 402 | 0.020 |
Why?
| | Sex Distribution | 1 | 2005 | 395 | 0.020 |
Why?
| | Risk Assessment | 2 | 2005 | 3137 | 0.020 |
Why?
| | Brain | 1 | 1996 | 2664 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 4550 | 0.020 |
Why?
| | Hoarseness | 1 | 2001 | 4 | 0.010 |
Why?
| | Laryngeal Muscles | 1 | 2001 | 5 | 0.010 |
Why?
| | Pyridostigmine Bromide | 1 | 2001 | 3 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2001 | 37 | 0.010 |
Why?
| | Cholinesterase Inhibitors | 1 | 2001 | 23 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 2001 | 127 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2001 | 195 | 0.010 |
Why?
| | Medical History Taking | 1 | 2001 | 127 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2001 | 196 | 0.010 |
Why?
| | Drug Therapy | 1 | 2001 | 83 | 0.010 |
Why?
| | Steroids | 1 | 2001 | 135 | 0.010 |
Why?
| | Retrospective Studies | 3 | 2001 | 11118 | 0.010 |
Why?
| | Drug Utilization | 1 | 2001 | 182 | 0.010 |
Why?
| | Incidence | 1 | 2005 | 2453 | 0.010 |
Why?
| | Speech Reception Threshold Test | 1 | 1998 | 4 | 0.010 |
Why?
| | Reflex, Vestibulo-Ocular | 1 | 1998 | 9 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1430 | 0.010 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 1 | 1998 | 51 | 0.010 |
Why?
| | Child | 1 | 1996 | 17358 | 0.010 |
Why?
| | Adolescent | 1 | 1996 | 18579 | 0.010 |
Why?
| | Prognosis | 1 | 2005 | 3532 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2001 | 460 | 0.010 |
Why?
| | Chronic Disease | 1 | 2002 | 1666 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2005 | 6779 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2001 | 1206 | 0.010 |
Why?
| | Risk Factors | 1 | 2001 | 8979 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2001 | 8944 | 0.010 |
Why?
|
|
Abaza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|